Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2UP6Z)

Drug Name

ARO-AAT Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alopecia	ED70	Phase 2	[1]
Alpha-1 antitrypsin deficiency	5C5A	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SERPINA1 messenger RNA (SERPINA1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fazirsiran	DM772MW	Alpha-1 antitrypsin deficiency	5C5A	Phase 3	[4]
Belcesiran	DMLMIGI	Alpha-1 antitrypsin deficiency	5C5A	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SERPINA1 messenger RNA (SERPINA1 mRNA)	TT2L4TV	A1AT_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03946449) Study of ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD). U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT03362242) Study of ARO-AAT in Normal Adult Volunteers. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
4	Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524.
5	Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals